# Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

> **NCT03584165** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **NightstaRx Ltd, a Biogen Company** · enrollment: 330 (estimated)

## Conditions studied

- Choroideremia
- X-Linked Retinitis Pigmentosa

## Interventions

- **GENETIC:** BIIB111
- **GENETIC:** BIIB112

## Key facts

- **NCT ID:** NCT03584165
- **Lead sponsor:** NightstaRx Ltd, a Biogen Company
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2018-06-04
- **Primary completion:** 2026-06-04
- **Final completion:** 2026-06-04
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03584165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03584165, "Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03584165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*